{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:49:12Z","timestamp":1774694952650,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R37AI153025"],"award-info":[{"award-number":["R37AI153025"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DP2EB024245"],"award-info":[{"award-number":["DP2EB024245"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21CA236640, R33CA247739"],"award-info":[{"award-number":["R21CA236640, R33CA247739"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000185","name":"Defense Advanced Research Projects Agency","doi-asserted-by":"publisher","award":["D19AP00024"],"award-info":[{"award-number":["D19AP00024"]}],"id":[{"id":"10.13039\/100000185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Med"],"DOI":"10.1186\/s10020-025-01420-1","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:11:30Z","timestamp":1774685490000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD4 T-cell platform for delivering interferons as an antiviral countermeasure with a focus on SARS-CoV-2"],"prefix":"10.1186","volume":"32","author":[{"given":"Xiaohe","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin A.","family":"Ssemadaali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harikrishnan","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Arredondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold S.","family":"Javitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satya","family":"Dandekar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parijat","family":"Bhatnagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"1420_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41577-020-0346-x","volume":"20","author":"D Acharya","year":"2020","unstructured":"Acharya D, Liu G, Gack MU. Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020;20:397\u20138.","journal-title":"Nat Rev Immunol"},{"key":"1420_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.mib.2008.05.015","volume":"11","author":"E Bartee","year":"2008","unstructured":"Bartee E, Mohamed MR, McFadden G. Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol. 2008;11:378\u201383.","journal-title":"Curr Opin Microbiol"},{"key":"1420_CR3","unstructured":"Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, B\u00e9ziat V, Manry J, Shaw E, Haljasmagi L, Peterson P, Lorenzo L, Bizien L, Trouillet-Assant S, Dobbs K, de Jesus AA, Belot A, Kallaste A, Catherinot E, Tandjaoui-Lambiotte Y, Le Pen J, Kerner G, Bigio B, Seeleuthner Y, Yang R, Bolze A, Spaan AN, Delmonte OM, Abers MS, Aiuti A, Casari G, Lampasona V, Piemonti L, Ciceri F, Bilguvar K, Lifton RP, Vasse M, Smadja DM, Migaud M, Hadjadj J, Terrier B, Duffy D, Quintana-Murci L, van de Beek D, Roussel L, Vinh DC, Tangye SG, Haerynck F, Dalmau D, Martinez-Picado J, Brodin P, Nussenzweig MC, Boisson-Dupuis S, Rodriguez-Gallego C, Vogt G, Mogensen TH, Oler AJ, Gu J, Burbelo PD, Cohen JI, Biondi A, Bettini LR, D'Angio M, Bonfanti P, Rossignol P, Mayaux J, Rieux-Laucat F, Husebye ES, Fusco F, Ursini MV, Imberti L, Sottini A, Paghera S, Quiros-Roldan E, Rossi C, Castagnoli R, Montagna D, Licari A, Marseglia GL, Duval X, Ghosn J, Lab H, Group NUIRtC, Clinicians C, Clinicians CS, Imagine CG, French CCSG, Milieu Interieur C, VCCCo, Amsterdam UMCCB, Effort CHG, Tsang JS, Goldbach-Mansky R, Kisand K, Lionakis MS, Puel A, Zhang SY, Holland SM, Gorochov G, Jouanguy E, Rice CM, Cobat A, Notarangelo LD, Abel L, Su HC, Casanova JL. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370(6515)."},{"key":"1420_CR4","doi-asserted-by":"crossref","unstructured":"Bastard P, Orlova E, Sozaeva L, L\u00e9vy R, James A, Schmitt MM, Ochoa S, Kareva M, Rodina Y, Gervais A, Le Voyer T, Rosain J, Philippot Q, Neehus AL, Shaw E, Migaud M, Bizien L, Ekwall O, Berg S, Beccuti G, Ghizzoni L, Thiriez G, Pavot A, Goujard C, Fremond ML, Carter E, Rothenbuhler A, Linglart A, Mignot B, Comte A, Cheikh N, Hermine O, Breivik L, Husebye ES, Humbert S, Rohrlich P, Coaquette A, Vuoto F, Faure K, Mahlaoui N. Kotnik P, Battelino T, Trebusak Podkrajsek K, Kisand K, Ferre EMN, DiMaggio T, Rosen LB, Burbelo PD, McIntyre M, Kann NY, Shcherbina A, Pavlova M, Kolodkina A, Holland SM, Zhang SY, Crow YJ, Notarangelo LD, Su HC, Abel L, Anderson MS, Jouanguy E, Neven B, Puel A, Casanova JL, Lionakis MS. Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1. J Exp Med. 2021;218(7).","DOI":"10.1084\/jem.20210554"},{"key":"1420_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.mib.2016.05.015","volume":"32","author":"DC Beachboard","year":"2016","unstructured":"Beachboard DC, Horner SM. Innate immune evasion strategies of DNA and RNA viruses. Curr Opin Microbiol. 2016;32:113\u20139.","journal-title":"Curr Opin Microbiol"},{"key":"1420_CR6","doi-asserted-by":"publisher","first-page":"e1009427","DOI":"10.1371\/journal.ppat.1009427","volume":"17","author":"P Bessiere","year":"2021","unstructured":"Bessiere P, Wasniewski M, Picard-Meyer E, Servat A, Figueroa T, Foret-Lucas C, et al. Intranasal type I interferon treatment is beneficial only when administered before clinical signs onset in the SARS-CoV-2 hamster model. PLoS Pathog. 2021;17:e1009427.","journal-title":"PLoS Pathog"},{"key":"1420_CR7","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","volume":"181","author":"D Blanco-Melo","year":"2020","unstructured":"Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. 2020;181:1036-1045 e1039.","journal-title":"Cell"},{"key":"1420_CR8","doi-asserted-by":"crossref","unstructured":"Busnadiego I, Fernbach S, Pohl MO, Karakus U, Huber M, Trkola A, Stertz S, Hale BG. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2. mBio. 2020;11(5).","DOI":"10.1128\/mBio.01928-20"},{"key":"1420_CR9","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","volume":"19","author":"R Channappanavar","year":"2016","unstructured":"Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19:181\u201393.","journal-title":"Cell Host Microbe"},{"key":"1420_CR10","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1172\/JCI126363","volume":"129","author":"R Channappanavar","year":"2019","unstructured":"Channappanavar R, Fehr AR, Zheng J, Wohlford-Lenane C, Abrahante JE, Mack M, et al. IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes. J Clin Invest. 2019;129:3625\u201339.","journal-title":"J Clin Invest"},{"key":"1420_CR11","doi-asserted-by":"publisher","first-page":"102456","DOI":"10.1016\/j.coi.2024.102456","volume":"89","author":"JJM Chuah","year":"2024","unstructured":"Chuah JJM, Campbell NK. IFN\u03b5, IFN\u03c9 and IFN\u03bb: interferons defending the mucosa. Curr Opin Immunol. 2024;89:102456.","journal-title":"Curr Opin Immunol"},{"key":"1420_CR12","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.15252\/emmm.201606413","volume":"8","author":"S Davidson","year":"2016","unstructured":"Davidson S, McCabe TM, Crotta S, Gad HH, Hessel EM, Beinke S, et al. IFN\u03bb is a potent anti-influenza therapeutic without the inflammatory side effects of IFN\u03b1 treatment. EMBO Mol Med. 2016;8:1099\u2013112.","journal-title":"EMBO Mol Med"},{"key":"1420_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1128\/iai.8.3.309-316.1973","volume":"8","author":"E De Clercq","year":"1973","unstructured":"De Clercq E, Stewart WE 2nd, De Somer P. Studies on the mechanism of the priming effect of interferon on interferon production by cell cultures exposed to poly(rI)-poly(rC). Infect Immun. 1973;8:309\u201316.","journal-title":"Infect Immun"},{"key":"1420_CR14","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"key":"1420_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","volume":"586","author":"KH Dinnon 3rd","year":"2020","unstructured":"Dinnon KH 3rd, Leist SR, Schafer A, Edwards CE, Martinez DR, Montgomery SA, et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature. 2020;586:560\u20136.","journal-title":"Nature"},{"key":"1420_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1089\/hum.2011.138","volume":"23","author":"JE Doherty","year":"2012","unstructured":"Doherty JE, Huye LE, Yusa K, Zhou L, Craig NL, Wilson MH. Hyperactive piggyBac gene transfer in human cells and in vivo. Hum Gene Ther. 2012;23:311\u201320.","journal-title":"Hum Gene Ther"},{"key":"1420_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1099\/0022-1317-43-1-247","volume":"43","author":"JM Emeny","year":"1979","unstructured":"Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol. 1979;43:247\u201352.","journal-title":"J Gen Virol"},{"key":"1420_CR18","first-page":"266","volume":"23","author":"KP Fabian","year":"2021","unstructured":"Fabian KP, Hodge JW. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. Mol Ther. 2021;23:266\u201376.","journal-title":"Mol Ther"},{"key":"1420_CR19","doi-asserted-by":"publisher","first-page":"e2203760119","DOI":"10.1073\/pnas.2203760119","volume":"119","author":"K Guo","year":"2022","unstructured":"Guo K, Barrett BS, Morrison JH, Mickens KL, Vladar EK, Hasenkrug KJ, et al. Interferon resistance of emerging SARS-CoV-2 variants. Proc Natl Acad Sci U S A. 2022;119:e2203760119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1420_CR20","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","volume":"385","author":"A Gupta","year":"2021","unstructured":"Gupta A, Gonzalez-Rojas Y, Juarez E, Crespo Casal M, Moya J, Falci DR, et al. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. N Engl J Med. 2021;385:1941\u201350.","journal-title":"N Engl J Med."},{"key":"1420_CR21","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/vim.2020.0076","volume":"34","author":"A Jafarzadeh","year":"2021","unstructured":"Jafarzadeh A, Nemati M, Saha B, Bansode YD, Jafarzadeh S. Protective potentials of type III interferons in COVID-19 patients: lessons from differential properties of type I- and III interferons. Viral Immunol. 2021;34:307\u201320.","journal-title":"Viral Immunol"},{"key":"1420_CR22","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1038\/s41467-021-22177-1","volume":"12","author":"P Jagannathan","year":"2021","unstructured":"Jagannathan P, Andrews JR, Bonilla H, Hedlin H, Jacobson KB, Balasubramanian V, et al. Peginterferon lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial. Nat Commun. 2021;12:1967.","journal-title":"Nat Commun"},{"key":"1420_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-022-04702-4","volume":"606","author":"C Junqueira","year":"2022","unstructured":"Junqueira C, Crespo \u00c2, Ranjbar S, De Lacerda LB, Lewandrowski M, Ingber J, et al. FcgammaR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature. 2022;606:576\u201384.","journal-title":"Nature."},{"key":"1420_CR24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000503030","volume":"12","author":"M Kikkert","year":"2020","unstructured":"Kikkert M. Innate immune evasion by human respiratory RNA viruses. J Innate Immun. 2020;12:4\u201320.","journal-title":"J Innate Immun"},{"key":"1420_CR25","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1038\/s12276-021-00592-0","volume":"53","author":"Y-M Kim","year":"2021","unstructured":"Kim Y-M, Shin E-C. Type I and III interferon responses in SARS-CoV-2 infection. Exp Mol Med. 2021;53:750\u201360.","journal-title":"Exp Mol Med"},{"key":"1420_CR26","first-page":"68","volume":"2","author":"HG Klingemann","year":"1996","unstructured":"Klingemann HG, Wong E, Maki G. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood. Bio Blood Marrow Transplant. 1996;2:68\u201375.","journal-title":"Bio Blood Marrow Transplant"},{"key":"1420_CR27","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","volume":"7","author":"H Klingemann","year":"2016","unstructured":"Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy - advantages of the NK-92 cell line over blood NK cells. Front Immunol. 2016;7:91.","journal-title":"Front Immunol"},{"key":"1420_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41577-020-00429-3","volume":"20","author":"JS Lee","year":"2020","unstructured":"Lee JS, Shin EC. The type I interferon response in COVID-19: implications for treatment. Nat Rev Immunol. 2020;20:585\u20136.","journal-title":"Nat Rev Immunol"},{"key":"1420_CR29","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1038\/s41467-020-17665-9","volume":"11","author":"X Lei","year":"2020","unstructured":"Lei X, Dong X, Ma R, Wang W, Xiao X, Tian Z, et al. Activation and evasion of type I interferon responses by SARS-CoV-2. Nat Commun. 2020;11:3810.","journal-title":"Nat Commun"},{"key":"1420_CR30","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1080\/07853890.2021.1890329","volume":"53","author":"C Li","year":"2021","unstructured":"Li C, Luo F, Liu C, Xiong N, Xu Z, Zhang W, et al. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial. Ann Med. 2021;53:391\u2013401.","journal-title":"Ann Med"},{"key":"1420_CR31","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.cytogfr.2014.07.015","volume":"25","author":"FC Lin","year":"2014","unstructured":"Lin FC, Young HA. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 2014;25:369\u201376.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1420_CR32","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"1420_CR33","doi-asserted-by":"crossref","unstructured":"Lokugamage KG, Hage A, de Vries M, Valero-Jimenez AM, Schindewolf C, Dittmann M, Rajsbaum R, Menachery VD. Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV. J Virol. 2020;94(23).","DOI":"10.1128\/JVI.01410-20"},{"key":"1420_CR34","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1038\/s41467-022-30216-8","volume":"13","author":"T Lu","year":"2022","unstructured":"Lu T, Ma R, Dong W, Teng K-Y, Kollath DS, Li Z, et al. Off-the-shelf CAR natural killer cells secreting IL-15 target spike in treating COVID-19. Nat Commun. 2022;13:2576.","journal-title":"Nat Commun"},{"key":"1420_CR35","doi-asserted-by":"publisher","first-page":"652223","DOI":"10.3389\/fimmu.2021.652223","volume":"12","author":"MT Ma","year":"2021","unstructured":"Ma MT, Badeti S, Chen CH, Kim J, Choudhary A, Honnen B, et al. CAR-NK cells effectively target SARS-CoV-2-spike-expressing cell lines in vitro. Front Immunol. 2021;12:652223.","journal-title":"Front Immunol"},{"key":"1420_CR36","doi-asserted-by":"publisher","first-page":"e88","DOI":"10.1002\/cpz1.88","volume":"1","author":"M Madrid","year":"2021","unstructured":"Madrid M, Sumen C, Aivio S, Saklayen N. Autologous induced pluripotent stem cell-based cell therapies: promise, progress, and challenges. Curr Protoc. 2021;1:e88.","journal-title":"Curr Protoc"},{"key":"1420_CR37","doi-asserted-by":"publisher","first-page":"n2422","DOI":"10.1136\/bmj.n2422","volume":"375","author":"E Mahase","year":"2021","unstructured":"Mahase E. Covid-19: molnupiravir reduces risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021;375:n2422.","journal-title":"BMJ"},{"key":"1420_CR38","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.abc2061","volume":"369","author":"J Major","year":"2020","unstructured":"Major J, Crotta S, Llorian M, McCabe TM, Gad HH, Priestnall SL, et al. Type I and III interferons disrupt lung epithelial repair during recovery from viral infection. Science. 2020;369:712\u20137.","journal-title":"Science"},{"key":"1420_CR39","doi-asserted-by":"publisher","first-page":"104811","DOI":"10.1016\/j.antiviral.2020.104811","volume":"179","author":"E Mantlo","year":"2020","unstructured":"Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res. 2020;179:104811.","journal-title":"Antiviral Res"},{"key":"1420_CR40","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12101198","author":"I Mart\u00ednez-Espinoza","year":"2024","unstructured":"Mart\u00ednez-Espinoza I, Babawale PI, Miletello H, Cheemarla NR, Guerrero-Plata A. Interferon epsilon-mediated antiviral activity against human metapneumovirus and respiratory syncytial virus. Vaccines. 2024. https:\/\/doi.org\/10.3390\/vaccines12101198.","journal-title":"Vaccines"},{"key":"1420_CR41","doi-asserted-by":"publisher","first-page":"920","DOI":"10.2174\/1568026621666210429083050","volume":"21","author":"Z Meng","year":"2021","unstructured":"Meng Z, Wang T, Chen L, Chen X, Li L, Qin X, et al. The effect of recombinant human interferon alpha nasal drops to prevent COVID-19 pneumonia for medical staff in an epidemic area. Curr Top Med Chem. 2021;21:920\u20137.","journal-title":"Curr Top Med Chem"},{"key":"1420_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","volume":"9","author":"PD Monk","year":"2021","unstructured":"Monk PD, Marsden RJ, Tear VJ, Brookes J, Batten TN, Mankowski M, et al. Inhaled Interferon Beta, Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021;9:196\u2013206.","journal-title":"Lancet Respir Med."},{"key":"1420_CR43","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s13577-023-00942-2","volume":"36","author":"N Mukerjee","year":"2023","unstructured":"Mukerjee N, Maitra S, Ghosh A, Sharma R. Impact of CAR-T cell therapy on treating viral infections: unlocking the door to recovery. Hum Cell. 2023;36:1839\u201342.","journal-title":"Hum Cell"},{"key":"1420_CR44","doi-asserted-by":"publisher","first-page":"e10434","DOI":"10.1002\/btm2.10434","volume":"8","author":"S Newmyer","year":"2023","unstructured":"Newmyer S, Ssemadaali MA, Radhakrishnan H, Javitz HS, Bhatnagar P. Electrically regulated cell-based intervention for viral infections. Bioeng Transl Med. 2023;8:e10434.","journal-title":"Bioeng Transl Med"},{"key":"1420_CR45","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/bmt.2016.17","volume":"51","author":"RJ O'Reilly","year":"2016","unstructured":"O\u2019Reilly RJ, Prockop S, Hasan AN, Koehne G, Doubrovina E. Virus-specific T-cell banks for \u201coff the shelf\u201d adoptive therapy of refractory infections. Bone Marrow Transplant. 2016;51:1163\u201372.","journal-title":"Bone Marrow Transplant"},{"key":"1420_CR46","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","volume":"27","author":"A Park","year":"2020","unstructured":"Park A, Iwasaki A. Type I and type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27:870\u20138.","journal-title":"Cell Host Microbe"},{"key":"1420_CR47","doi-asserted-by":"publisher","first-page":"e1900288","DOI":"10.1002\/adbi.201900288","volume":"4","author":"H Radhakrishnan","year":"2020","unstructured":"Radhakrishnan H, Javitz HS, Bhatnagar P. Lentivirus manufacturing process for primary T-cell biofactory production. Adv Biosyst. 2020;4:e1900288.","journal-title":"Adv Biosyst"},{"key":"1420_CR48","doi-asserted-by":"publisher","unstructured":"Radhakrishnan H, Newmyer S, Ssemadaali MA, Javitz HS, Bhatnagar P. Primary T\u2010cell\u2010based delivery platform for in vivo synthesis of engineered proteins. Bioeng Transl Med. 2023:e10605.https:\/\/doi.org\/10.1002\/BTM2.10605.","DOI":"10.1002\/BTM2.10605"},{"key":"1420_CR49","doi-asserted-by":"publisher","first-page":"e2318687121","DOI":"10.1073\/pnas.2318687121","volume":"121","author":"H Radhakrishnan","year":"2024","unstructured":"Radhakrishnan H, Newmyer SL, Javitz HS, Bhatnagar P. Engineered CD4 T cells for in vivo delivery of therapeutic proteins. Proc Natl Acad Sci USA. 2024;121:e2318687121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1420_CR50","doi-asserted-by":"crossref","unstructured":"Rebendenne A, Valad\u00e3o ALC, Tauziet M, Maarifi G, Bonaventure B, McKellar J, Plan\u00e8s R, Nisole S, Arnaud-Arnould M, Moncorg\u00e9 O, Goujon C. SARS-CoV-2 triggers an MDA-5-dependent interferon response which is unable to control replication in lung epithelial cells. J Virol. 2021;95(8).","DOI":"10.1128\/JVI.02415-20"},{"key":"1420_CR51","doi-asserted-by":"publisher","first-page":"e1800210","DOI":"10.1002\/adbi.201800210","volume":"2","author":"CE Repellin","year":"2018","unstructured":"Repellin CE, Patel P, Beviglia L, Javitz H, Sambucetti L, Bhatnagar P. Modular antigen-specific T-cell biofactories for calibrated in vivo synthesis of engineered proteins. Adv Biosyst. 2018;2:e1800210.","journal-title":"Adv Biosyst"},{"key":"1420_CR52","doi-asserted-by":"publisher","first-page":"e1900224","DOI":"10.1002\/adbi.201900224","volume":"4","author":"CE Repellin","year":"2020","unstructured":"Repellin CE, Ganesan P, Alcudia JF, Lakshmireddy HKD, Patel P, Beviglia L, et al. Engineered ovarian cancer cell lines for validation of CAR T cell function. Adv Biosyst. 2020;4:e1900224.","journal-title":"Adv Biosyst"},{"key":"1420_CR53","doi-asserted-by":"publisher","first-page":"e2000298","DOI":"10.1002\/adbi.202000298","volume":"5","author":"CE Repellin","year":"2021","unstructured":"Repellin CE, Ssemadaali MA, Newmyer S, Radhakrishnan H, Javitz HS, Bhatnagar P. NK-cell biofactory as an off-the-shelf cell-based vector for targeted in situ synthesis of engineered proteins. Adv Biol. 2021;5:e2000298.","journal-title":"Adv Biol"},{"key":"1420_CR54","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1080\/10428194.2018.1443449","volume":"59","author":"TM Robinson","year":"2018","unstructured":"Robinson TM, Prince GT, Thoburn C, Warlick E, Ferguson A, Kasamon YL, et al. Pilot trial of K562\/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma. 2018;59:2801\u201311.","journal-title":"Leuk Lymphoma"},{"key":"1420_CR55","doi-asserted-by":"publisher","first-page":"104791","DOI":"10.1016\/j.antiviral.2020.104791","volume":"178","author":"E Sallard","year":"2020","unstructured":"Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N. Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020;178:104791.","journal-title":"Antiviral Res"},{"key":"1420_CR56","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018;8:958\u201371.","journal-title":"Cancer Discov"},{"key":"1420_CR57","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-021-03594-0","volume":"594","author":"KO Saunders","year":"2021","unstructured":"Saunders KO, Lee E, Parks R, Martinez DR, Li D, Chen H, et al. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses. Nature. 2021;594:553\u20139.","journal-title":"Nature"},{"key":"1420_CR58","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.immuni.2023.06.018","volume":"56","author":"R Savan","year":"2023","unstructured":"Savan R, Gale M Jr. Innate immunity and interferon in SARS-CoV-2 infection outcome. Immunity. 2023;56:1443\u201350.","journal-title":"Immunity"},{"key":"1420_CR59","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","volume":"32","author":"WM Schneider","year":"2014","unstructured":"Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513\u201345.","journal-title":"Annu Rev Immunol"},{"key":"1420_CR60","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3389\/fimmu.2019.02711","volume":"10","author":"M Seif","year":"2019","unstructured":"Seif M, Einsele H, L\u00f6ffler J. CAR T cells beyond cancer: hope for immunomodulatory therapy of infectious diseases. Front Immunol. 2019;10:2711.","journal-title":"Front Immunol"},{"key":"1420_CR61","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","volume":"19","author":"N Shimasaki","year":"2020","unstructured":"Shimasaki N, Jain A, Campana D. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020;19:200\u201318.","journal-title":"Nat Rev Drug Discov"},{"key":"1420_CR62","doi-asserted-by":"publisher","first-page":"e0073122","DOI":"10.1128\/spectrum.00731-22","volume":"10","author":"MA Ssemadaali","year":"2022","unstructured":"Ssemadaali MA, Newmyer S, Radhakrishnan H, Arredondo J, Javitz HS, Dandekar S, et al. Cell-based platform for antigen testing and its application for SARS-CoV-2 infection. Microbiol Spectr. 2022;10:e0073122.","journal-title":"Microbiol Spectr"},{"key":"1420_CR63","doi-asserted-by":"publisher","first-page":"e10508","DOI":"10.1002\/btm2.10508","volume":"8","author":"MA Ssemadaali","year":"2023","unstructured":"Ssemadaali MA, Arredondo J, Buser EA, Newmyer S, Radhakrishnan H, Javitz HS, et al. Genetically engineered pair of cells for serological testing and its application for SARS-CoV-2. Bioeng Transl Med. 2023;8:e10508.","journal-title":"Bioeng Transl Med"},{"key":"1420_CR64","doi-asserted-by":"publisher","unstructured":"Stanifer ML, Kee C, Cortese M, Triana S, Mukenhirn M, Kraeusslich HG, Alexandrov T, Bartenschlager R, Boulant S. Critical role of type III interferon in controlling SARS-CoV-2 infection, replication and spread in primary human intestinal epithelial cells. bioRxiv : the preprint server for biology. 2020 https:\/\/doi.org\/10.1101\/2020.04.24.059667, 2020.2004.2024.059667.","DOI":"10.1101\/2020.04.24.059667"},{"key":"1420_CR65","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-020-00306-4","volume":"5","author":"Z Wang","year":"2020","unstructured":"Wang Z, Pan H, Jiang B. Type I IFN deficiency: an immunological characteristic of severe COVID-19 patients. Signal Transduct Target Ther. 2020;5:198.","journal-title":"Signal Transduct Target Ther"},{"key":"1420_CR66","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07853890.2022.2034936","volume":"54","author":"W Wen","year":"2022","unstructured":"Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54:516\u201323.","journal-title":"Ann Med"},{"key":"1420_CR67","doi-asserted-by":"publisher","first-page":"110812","DOI":"10.1016\/j.celrep.2022.110812","volume":"39","author":"K Westendorf","year":"2022","unstructured":"Westendorf K, Zentelis S, Wang L, Foster D, Vaillancourt P, Wiggin M, et al. LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Rep. 2022;39:110812.","journal-title":"Cell Rep"},{"key":"1420_CR68","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.cell.2020.05.047","volume":"181","author":"Wrapp","year":"2020","unstructured":"Wrapp, De Vlieger D, Corbett KS, Torres GM, Wang N, Van Breedam W, et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell. 2020;181:1436\u201341.","journal-title":"Cell."},{"key":"1420_CR69","doi-asserted-by":"publisher","first-page":"108234","DOI":"10.1016\/j.celrep.2020.108234","volume":"33","author":"H Xia","year":"2020","unstructured":"Xia H, Cao Z, Xie X, Zhang X, Chen JY, Wang H, et al. Evasion of type I interferon by SARS-CoV-2. Cell Rep. 2020;33:108234.","journal-title":"Cell Rep"},{"key":"1420_CR70","doi-asserted-by":"crossref","unstructured":"Zaki MM, Lesha E, Said K, Kiaee K, Robinson-McCarthy L, George H, Hanna A, Appleton E, Liu S, Ng AHM, Khoshakhlagh P, Church GM. Cell therapy strategies for COVID-19: Current approaches and potential applications. Sci Adv. 2021;7(33).","DOI":"10.1126\/sciadv.abg5995"},{"key":"1420_CR71","doi-asserted-by":"crossref","unstructured":"Zeng C, Evans JP, King T, Zheng YM, Oltz EM, Whelan SPJ, Saif LJ, Peeples ME, Liu SL. SARS-CoV-2 spreads through cell-to-cell transmission. Proc Natl Acad Sci U S A. 2022;119(1).","DOI":"10.1073\/pnas.2111400119"},{"key":"1420_CR72","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3389\/fimmu.2017.00533","volume":"8","author":"C Zhang","year":"2017","unstructured":"Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, et al. Chimeric antigen receptor-engineered NK-92 cells: an off-the-shelf cellular therapeutic for targeted elimination of cancer cells and induction of protective antitumor immunity. Front Immunol. 2017;8:533.","journal-title":"Front Immunol"},{"key":"1420_CR73","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3389\/fimmu.2020.01061","volume":"11","author":"Q Zhou","year":"2020","unstructured":"Zhou Q, Chen V, Shannon CP, Wei XS, Xiang X, Wang X, et al. Interferon-alpha2b treatment for COVID-19. Front Immunol. 2020;11:1061.","journal-title":"Front Immunol"},{"key":"1420_CR74","doi-asserted-by":"publisher","first-page":"eabi9215","DOI":"10.1126\/scitranslmed.abi9215","volume":"14","author":"P Zhou","year":"2022","unstructured":"Zhou P, Yuan M, Song G, Beutler N, Shaabani N, Huang D, et al. A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection. Sci Transl Med. 2022;14:eabi9215.","journal-title":"Sci Transl Med"}],"container-title":["Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01420-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10020-025-01420-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10020-025-01420-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T10:01:40Z","timestamp":1774692100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10020-025-01420-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1420"],"URL":"https:\/\/doi.org\/10.1186\/s10020-025-01420-1","relation":{},"ISSN":["1528-3658"],"issn-type":[{"value":"1528-3658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"23 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"PB is a Founder of Tribe Research, a nonprofit research entity. HSJ owns Javitz Statistical Consulting. All other authors declare no competing financial interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}